Antimalarials have been used in the treatment of lupus erythematosus since 1894. 1 They have also been used in the treatment of diverse rheumatologic and dermatologic diseases such as rheumatoid arthritis, dermatomyositis, oral lichen planus, sarcoidosis. 1, 2 They are perhaps the most widely prescribed medications in the treatment of discoid lupus erythematosus.
Proteins that enter cells through endocytosis are delivered to endosomes, which become increasingly acidic as they progress into the interior of the cell, eventually fusing with lysosomes. The endosomes and lysosomes contain proteases, known as acid proteases, which are activated at low PH and eventually degrade the protein antigens contained in the vesicles. Larger particulate material internalised by phagocytosis or micropinocytosis can also be handled by this pathway of antigen processing. 3 Chloroquine and hydroxychloroquine are weak bases, which accumulate in the acidic environment of lysosomes and raise intra-lysosomal pH levels, with the resultant decreased ability of macrophages to process antigens. 2, 4 Moreover, they decrease the lysosomal size and possibly inhibit their function as well, hence exerting anti-inflammatory effects. 2 The proton pump inhibitors omeprazole, lansoprazole, pantoprazole, esomeprazole and rabeprazole suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase at the secretory surface of the gastric parietal cells. 5 Blocking the same pump on the lysosomal membrane can lead to an increase of endo-lysosomal pH. Noteworthy, omeprazole has been shown to exert in-vitro antimalarial 6 and, more importantly, in-vivo antileishmanial activities 7 because of the blockade of this pump on parasitic acid food vacuoles and parasite-containing phagolysosomes of human macrophages, respectively.
Because chloroquine/hydroxychloroquine and proton pump inhibitors are weak bases that tend to accumulate in acidic environments, 6 competition with proton pump inhibitors and/or a higher pH would inhibit the accumulation of chloroquine/hydroxychloroquine at their site of action, hence mitigating the immunomodulatory effects of these agents. In addition, the accumulation of chloroquine may be driven by a P-type ATPase, 6, 8 which may be inhibited by omeprazole. The in-vitro studies of Skinner-Adams and Davis 6 elegantly shows that because of these rationales, omeprazole-chloroquine combination has antagonising anti-malarial activity, but omeprazolequinine combination has synergistic antimalarial activity because unlike chloroquine, quinine is more lipophilic and is not concentrated exclusively in food vacuoles.
Therefore, the potential antagonising effect of proton pump inhibitors on the immunopharmacologic actions of chloroquine and hydroxychloroquine should be born in mind when facing unresponsive to antimalarials. 
